

Bionor Immuno AS

[View the current Bionor Immuno AS Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/19671-Bionor+Immuno+AS.html)

(<http://www.bioportfolio.com/biocorporate/19671-Bionor+Immuno+AS.html>)

Contact Details:

P.O. Box 1823

Skien

3703

Norway

Tel: 47 35 50 57 50

Fax: 47 35 50 57 01

Email: info@bionorimmuno.com

Bionor Immuno is a multidisciplinary drug discovery company located in Skien, Norway. The major focus of the company is to develop effective peptide based immunotherapies, against infectious diseases for which there is currently no effective vaccine or where existing treatments are poorly effective. Bionor Immuno AS aims to develop its therapeutic products through phase II clinical trials. Phase III clinical trials, manufacturing and marketing of finished products will be done in co-operation with a licensing partner

Recent Publications by Bionor Immuno AS:



- [Circular CCR5 peptide conjugates and uses thereof \(WO2008074895\).](#)
*BACKGROUND: Several new strategies targeting HIV infection aim to inhibit...*27th October, 2009
Bionor Immuno AS, Klostergata 33, NO-3702 Skien, Norway.- Expert Opin Ther Pat. 2009 Sep;19(9):1323-8. ([DOI Direct Link](#))
- [Multiple antigen concentrations in delayed-type hypersensitivity \(DTH\) and response diversity during and after immunization with a peptide-based HIV-1 immunotherapy candidate \(Vacc-4x\).](#)
*Delayed-type hypersensitivity (DTH) testing represents a simple in vivo...*13th May, 2006
Bionor Immuno AS, P.O. Box. 1823, NO-3703 Skien, Norway.- Vaccine. 2006 Mar 6;24(10):1543-50. Epub 2005 Nov 2. ([DOI Direct Link](#))
- [Novel peptide-based HIV-1 immunotherapy.](#)
*Therapeutic immunisation of human immunodeficiency virus type 1-infected...*14th July, 2004
Bionor Immuno AS, Stromdaljordet 4, PO Box 1823 Gulset, NO-3703 Skien,- Expert Opin Biol Ther. 2004 Mar;4(3):349-61. ([DOI Direct Link](#))

Press Releases on Bionor Immuno AS:

Frost & Sullivan: Malaysia Diagnostics and Devices Industry Outlook 2009	21st August, 2009	Frost & Sullivan	KUALA LUMPUR, Malaysia, Aug. 21 /PRNewswire/ -- The current economic downturn has contributed to a significant shift in the Healthcare industry, but not for Malaysia. (Logo: http://www.newscom.com/cgi)
Cepheid Announces European Release of Improved Test for BCR-ABL Chromosomal Translocation Associated With Chronic Myelogenous Leukemia (CML)	17th June, 2009	Cepheid	Oncology Test Further Highlights Broad Market Applicability of GeneXpert System SUNNYVALE, Calif., June 17 /PRNewswire-FirstCall/ -- Cepheid (Nasdaq: CPHD) today announced the release of its
New Survey Reveals That More Than Half of Rheumatoid Arthritis Patients in Europe and Canada Feel Their Disease Controls Their Lives	10th June, 2009	Schering-Plough	Three-of-Four Patients Surveyed Experience Daily Pain From Rheumatoid Arthritis Despite Current Treatment; Findings Unveiled at the European League Against Rheumatism Annual Congress of Rheumatology DALLAS, Jan. 30 /PRNewswire-USNewswire/ -- Officials
Bernard Brigonnet Joins Baylor Research Institute as Vice President and Chief Operating Officer	30th January, 2009	Baylor Health Care System	with Baylor Health Care System announced today that Bernard Brigonnet will join the Baylor Research Institute (BRI) as vice president and chief
Nephros, Inc. Receives the 2009 Frost & Sullivan Medical Device Patient Care Company of the Year Award	14th January, 2009	Nephros, Inc.	RIVER EDGE, N.J., Jan. 14 /PRNewswire-FirstCall/ -- Nephros, Inc. (Amex: NEP), is pleased to announce that it has received the prestigious 2009 Frost & Sullivan Medical Device Patient Care Company

BioNews Results for Bionor Immuno AS



- [Researchers Find That Vacc-4x Therapeutic Peptide-Based HIV Vaccine Increases CD4 T-Cells in Chronically Infec](#)
 Yahoo! Canada: Oct 21 2009 12:17PM Matching: bionor immuno
- [Bionor Immuno Welcomes Renowned Virologist Robert Redfield, MD to Its Clinical Advisory Board](#)

Genetic Engineering News: Oct 21 2009 10:03AM Matching: bionor immuno

- [Bionor Immuno Welcomes Renowned Virologist Robert Redfield, MD to Its Clinical Advisory Board](#)
Individual.com: Oct 19 2009 2:07PM Matching: bionor immuno
- [Bionor Immuno Welcomes Renowned Virologist Robert Redfield, MD to Its Clinical Advisory Board](#)
Pharmacy Choice: Oct 19 2009 9:15PM Matching: bionor immuno

Bionor Immuno AS Clinical Trials:



- [Immunogenicity Study of Vacc-4x Versus Placebo in Patients Infected With HIV](#)

Bionor Immuno AS Patents:



- 7097971- [HIV-1 peptide, antigen, immunogenic composition, diagnostic method and immunoassay kit](#)
- 7009037- [Modified HIV-1gag p17 peptide and immunogenic composition](#)
- 6706859- [HIV peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by HIV](#)

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

